BIOMEDICINE & PHARMACOTHERAPY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=801280, encodeId=fc388012800b, content=垃圾杂志，收了一堆造假的，在国外毫无地位可言，最近的论文工厂全是来自中国医院的造假文章，真几把丢人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Sun Jul 05 02:35:04 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2167319, encodeId=30a4216e31940, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：综述;心血管 经验分享：稿号：6403 9.13 submitted to journal 10.05 with editor 10.06 under review 10.13 revise 10.25 revision submitted 10.26 with editor 10.26 under review 11.03 required review completed 11.04 with editor 11.05 revise 11.06 revision submitted 11.07 with editor 11.08 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bd78523149, createdName=ms5000001229064995, createdTime=Wed Nov 08 02:10:09 CST 2023, time=2023-11-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2153849, encodeId=e4ba215384983, content=审稿速度:6.0 经验分享：with editor 20天了，发邮件催了也没用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17405591072, createdName=ms3000000829910165, createdTime=Mon Aug 21 13:15:55 CST 2023, time=2023-08-21, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2109558, encodeId=04b12109558ba, content=我是投爱思唯尔旗下其他期刊，然后建议改投这个的。我以为系统改投会快点。26号转投的，现在还是submitted to journal。。。效率这么慢的吗？要拒也早点拒，改投其他也好啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/0de91724d2aa47e0a583df4b2c253a26/e5494d41881e4175a8e5538a29e52895.jpg, createdBy=ded46480201, createdName=HuangWong, createdTime=Mon Jan 09 20:31:49 CST 2023, time=2023-01-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2101266, encodeId=545d210126690, content=请问一直没有审稿人接受审稿，是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=950c5610679, createdName=ms5000000350323787, createdTime=Fri Nov 18 09:37:50 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238808, encodeId=2df91238808f8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：最近撤稿了很多小RNA的文章，这个杂志又被好几家医院预警了，不知道今年的中科院预警名单会不会再上呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Mon Aug 15 15:19:38 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229452, encodeId=0585122945216, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：呼吸;中西医 经验分享：under review快一个月了，一直没有审稿人接收怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42a35638390, createdName=ms8000002141105059, createdTime=Wed Jun 29 13:59:44 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111801, encodeId=085c211180196, content=成分研究+药效+网药+机制研究 10.20 投稿（要求上传原始数据） 11.17 重投 11.21 with editor 11.29～12.26 under review 12.26 返修 1.16 上传返修稿 1.18 第二次返修（要求上传路线图） 1.20上传 1.23 with editor 1.27 录用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sat Jan 28 09:22:33 CST 2023, time=2023-01-28, status=1, ipAttribution=新疆)]

2020-07-05 这是一个昵称

垃圾杂志，收了一堆造假的，在国外毫无地位可言，最近的论文工厂全是来自中国医院的造假文章，真几把丢人。

206 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=801280, encodeId=fc388012800b, content=垃圾杂志，收了一堆造假的，在国外毫无地位可言，最近的论文工厂全是来自中国医院的造假文章，真几把丢人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Sun Jul 05 02:35:04 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2167319, encodeId=30a4216e31940, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：综述;心血管 经验分享：稿号：6403 9.13 submitted to journal 10.05 with editor 10.06 under review 10.13 revise 10.25 revision submitted 10.26 with editor 10.26 under review 11.03 required review completed 11.04 with editor 11.05 revise 11.06 revision submitted 11.07 with editor 11.08 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bd78523149, createdName=ms5000001229064995, createdTime=Wed Nov 08 02:10:09 CST 2023, time=2023-11-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2153849, encodeId=e4ba215384983, content=审稿速度:6.0 经验分享：with editor 20天了，发邮件催了也没用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17405591072, createdName=ms3000000829910165, createdTime=Mon Aug 21 13:15:55 CST 2023, time=2023-08-21, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2109558, encodeId=04b12109558ba, content=我是投爱思唯尔旗下其他期刊，然后建议改投这个的。我以为系统改投会快点。26号转投的，现在还是submitted to journal。。。效率这么慢的吗？要拒也早点拒，改投其他也好啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/0de91724d2aa47e0a583df4b2c253a26/e5494d41881e4175a8e5538a29e52895.jpg, createdBy=ded46480201, createdName=HuangWong, createdTime=Mon Jan 09 20:31:49 CST 2023, time=2023-01-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2101266, encodeId=545d210126690, content=请问一直没有审稿人接受审稿，是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=950c5610679, createdName=ms5000000350323787, createdTime=Fri Nov 18 09:37:50 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238808, encodeId=2df91238808f8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：最近撤稿了很多小RNA的文章，这个杂志又被好几家医院预警了，不知道今年的中科院预警名单会不会再上呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Mon Aug 15 15:19:38 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229452, encodeId=0585122945216, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：呼吸;中西医 经验分享：under review快一个月了，一直没有审稿人接收怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42a35638390, createdName=ms8000002141105059, createdTime=Wed Jun 29 13:59:44 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111801, encodeId=085c211180196, content=成分研究+药效+网药+机制研究 10.20 投稿（要求上传原始数据） 11.17 重投 11.21 with editor 11.29～12.26 under review 12.26 返修 1.16 上传返修稿 1.18 第二次返修（要求上传路线图） 1.20上传 1.23 with editor 1.27 录用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sat Jan 28 09:22:33 CST 2023, time=2023-01-28, status=1, ipAttribution=新疆)]

2023-12-15 147ddcd3m55暂无昵称来自北京

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;综述
经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。

28 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=801280, encodeId=fc388012800b, content=垃圾杂志，收了一堆造假的，在国外毫无地位可言，最近的论文工厂全是来自中国医院的造假文章，真几把丢人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Sun Jul 05 02:35:04 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2167319, encodeId=30a4216e31940, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：综述;心血管 经验分享：稿号：6403 9.13 submitted to journal 10.05 with editor 10.06 under review 10.13 revise 10.25 revision submitted 10.26 with editor 10.26 under review 11.03 required review completed 11.04 with editor 11.05 revise 11.06 revision submitted 11.07 with editor 11.08 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bd78523149, createdName=ms5000001229064995, createdTime=Wed Nov 08 02:10:09 CST 2023, time=2023-11-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2153849, encodeId=e4ba215384983, content=审稿速度:6.0 经验分享：with editor 20天了，发邮件催了也没用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17405591072, createdName=ms3000000829910165, createdTime=Mon Aug 21 13:15:55 CST 2023, time=2023-08-21, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2109558, encodeId=04b12109558ba, content=我是投爱思唯尔旗下其他期刊，然后建议改投这个的。我以为系统改投会快点。26号转投的，现在还是submitted to journal。。。效率这么慢的吗？要拒也早点拒，改投其他也好啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/0de91724d2aa47e0a583df4b2c253a26/e5494d41881e4175a8e5538a29e52895.jpg, createdBy=ded46480201, createdName=HuangWong, createdTime=Mon Jan 09 20:31:49 CST 2023, time=2023-01-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2101266, encodeId=545d210126690, content=请问一直没有审稿人接受审稿，是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=950c5610679, createdName=ms5000000350323787, createdTime=Fri Nov 18 09:37:50 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238808, encodeId=2df91238808f8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：最近撤稿了很多小RNA的文章，这个杂志又被好几家医院预警了，不知道今年的中科院预警名单会不会再上呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Mon Aug 15 15:19:38 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229452, encodeId=0585122945216, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：呼吸;中西医 经验分享：under review快一个月了，一直没有审稿人接收怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42a35638390, createdName=ms8000002141105059, createdTime=Wed Jun 29 13:59:44 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111801, encodeId=085c211180196, content=成分研究+药效+网药+机制研究 10.20 投稿（要求上传原始数据） 11.17 重投 11.21 with editor 11.29～12.26 under review 12.26 返修 1.16 上传返修稿 1.18 第二次返修（要求上传路线图） 1.20上传 1.23 with editor 1.27 录用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sat Jan 28 09:22:33 CST 2023, time=2023-01-28, status=1, ipAttribution=新疆)]

2023-11-08 ms5000001229064995 来自湖南省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：综述;心血管
经验分享：稿号：6403 9.13 submitted to journal 10.05 with editor 10.06 under review 10.13 revise 10.25 revision submitted 10.26 with editor 10.26 under review 11.03 required review completed 11.04 with editor 11.05 revise 11.06 revision submitted 11.07 with editor 11.08 accept

52 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=801280, encodeId=fc388012800b, content=垃圾杂志，收了一堆造假的，在国外毫无地位可言，最近的论文工厂全是来自中国医院的造假文章，真几把丢人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Sun Jul 05 02:35:04 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2167319, encodeId=30a4216e31940, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：综述;心血管 经验分享：稿号：6403 9.13 submitted to journal 10.05 with editor 10.06 under review 10.13 revise 10.25 revision submitted 10.26 with editor 10.26 under review 11.03 required review completed 11.04 with editor 11.05 revise 11.06 revision submitted 11.07 with editor 11.08 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bd78523149, createdName=ms5000001229064995, createdTime=Wed Nov 08 02:10:09 CST 2023, time=2023-11-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2153849, encodeId=e4ba215384983, content=审稿速度:6.0 经验分享：with editor 20天了，发邮件催了也没用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17405591072, createdName=ms3000000829910165, createdTime=Mon Aug 21 13:15:55 CST 2023, time=2023-08-21, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2109558, encodeId=04b12109558ba, content=我是投爱思唯尔旗下其他期刊，然后建议改投这个的。我以为系统改投会快点。26号转投的，现在还是submitted to journal。。。效率这么慢的吗？要拒也早点拒，改投其他也好啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/0de91724d2aa47e0a583df4b2c253a26/e5494d41881e4175a8e5538a29e52895.jpg, createdBy=ded46480201, createdName=HuangWong, createdTime=Mon Jan 09 20:31:49 CST 2023, time=2023-01-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2101266, encodeId=545d210126690, content=请问一直没有审稿人接受审稿，是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=950c5610679, createdName=ms5000000350323787, createdTime=Fri Nov 18 09:37:50 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238808, encodeId=2df91238808f8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：最近撤稿了很多小RNA的文章，这个杂志又被好几家医院预警了，不知道今年的中科院预警名单会不会再上呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Mon Aug 15 15:19:38 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229452, encodeId=0585122945216, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：呼吸;中西医 经验分享：under review快一个月了，一直没有审稿人接收怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42a35638390, createdName=ms8000002141105059, createdTime=Wed Jun 29 13:59:44 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111801, encodeId=085c211180196, content=成分研究+药效+网药+机制研究 10.20 投稿（要求上传原始数据） 11.17 重投 11.21 with editor 11.29～12.26 under review 12.26 返修 1.16 上传返修稿 1.18 第二次返修（要求上传路线图） 1.20上传 1.23 with editor 1.27 录用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sat Jan 28 09:22:33 CST 2023, time=2023-01-28, status=1, ipAttribution=新疆)]

2023-08-21 ms3000000829910165 来自河南省

审稿速度:6.0
经验分享：with editor 20天了，发邮件催了也没用

50 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=801280, encodeId=fc388012800b, content=垃圾杂志，收了一堆造假的，在国外毫无地位可言，最近的论文工厂全是来自中国医院的造假文章，真几把丢人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Sun Jul 05 02:35:04 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2167319, encodeId=30a4216e31940, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：综述;心血管 经验分享：稿号：6403 9.13 submitted to journal 10.05 with editor 10.06 under review 10.13 revise 10.25 revision submitted 10.26 with editor 10.26 under review 11.03 required review completed 11.04 with editor 11.05 revise 11.06 revision submitted 11.07 with editor 11.08 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bd78523149, createdName=ms5000001229064995, createdTime=Wed Nov 08 02:10:09 CST 2023, time=2023-11-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2153849, encodeId=e4ba215384983, content=审稿速度:6.0 经验分享：with editor 20天了，发邮件催了也没用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17405591072, createdName=ms3000000829910165, createdTime=Mon Aug 21 13:15:55 CST 2023, time=2023-08-21, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2109558, encodeId=04b12109558ba, content=我是投爱思唯尔旗下其他期刊，然后建议改投这个的。我以为系统改投会快点。26号转投的，现在还是submitted to journal。。。效率这么慢的吗？要拒也早点拒，改投其他也好啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/0de91724d2aa47e0a583df4b2c253a26/e5494d41881e4175a8e5538a29e52895.jpg, createdBy=ded46480201, createdName=HuangWong, createdTime=Mon Jan 09 20:31:49 CST 2023, time=2023-01-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2101266, encodeId=545d210126690, content=请问一直没有审稿人接受审稿，是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=950c5610679, createdName=ms5000000350323787, createdTime=Fri Nov 18 09:37:50 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238808, encodeId=2df91238808f8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：最近撤稿了很多小RNA的文章，这个杂志又被好几家医院预警了，不知道今年的中科院预警名单会不会再上呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Mon Aug 15 15:19:38 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229452, encodeId=0585122945216, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：呼吸;中西医 经验分享：under review快一个月了，一直没有审稿人接收怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42a35638390, createdName=ms8000002141105059, createdTime=Wed Jun 29 13:59:44 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111801, encodeId=085c211180196, content=成分研究+药效+网药+机制研究 10.20 投稿（要求上传原始数据） 11.17 重投 11.21 with editor 11.29～12.26 under review 12.26 返修 1.16 上传返修稿 1.18 第二次返修（要求上传路线图） 1.20上传 1.23 with editor 1.27 录用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sat Jan 28 09:22:33 CST 2023, time=2023-01-28, status=1, ipAttribution=新疆)]

2023-01-09 HuangWong 来自广西

我是投爱思唯尔旗下其他期刊，然后建议改投这个的。我以为系统改投会快点。26号转投的，现在还是submitted to journal。。。效率这么慢的吗？要拒也早点拒，改投其他也好啊。

39 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=801280, encodeId=fc388012800b, content=垃圾杂志，收了一堆造假的，在国外毫无地位可言，最近的论文工厂全是来自中国医院的造假文章，真几把丢人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Sun Jul 05 02:35:04 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2167319, encodeId=30a4216e31940, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：综述;心血管 经验分享：稿号：6403 9.13 submitted to journal 10.05 with editor 10.06 under review 10.13 revise 10.25 revision submitted 10.26 with editor 10.26 under review 11.03 required review completed 11.04 with editor 11.05 revise 11.06 revision submitted 11.07 with editor 11.08 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bd78523149, createdName=ms5000001229064995, createdTime=Wed Nov 08 02:10:09 CST 2023, time=2023-11-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2153849, encodeId=e4ba215384983, content=审稿速度:6.0 经验分享：with editor 20天了，发邮件催了也没用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17405591072, createdName=ms3000000829910165, createdTime=Mon Aug 21 13:15:55 CST 2023, time=2023-08-21, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2109558, encodeId=04b12109558ba, content=我是投爱思唯尔旗下其他期刊，然后建议改投这个的。我以为系统改投会快点。26号转投的，现在还是submitted to journal。。。效率这么慢的吗？要拒也早点拒，改投其他也好啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/0de91724d2aa47e0a583df4b2c253a26/e5494d41881e4175a8e5538a29e52895.jpg, createdBy=ded46480201, createdName=HuangWong, createdTime=Mon Jan 09 20:31:49 CST 2023, time=2023-01-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2101266, encodeId=545d210126690, content=请问一直没有审稿人接受审稿，是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=950c5610679, createdName=ms5000000350323787, createdTime=Fri Nov 18 09:37:50 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238808, encodeId=2df91238808f8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：最近撤稿了很多小RNA的文章，这个杂志又被好几家医院预警了，不知道今年的中科院预警名单会不会再上呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Mon Aug 15 15:19:38 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229452, encodeId=0585122945216, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：呼吸;中西医 经验分享：under review快一个月了，一直没有审稿人接收怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42a35638390, createdName=ms8000002141105059, createdTime=Wed Jun 29 13:59:44 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111801, encodeId=085c211180196, content=成分研究+药效+网药+机制研究 10.20 投稿（要求上传原始数据） 11.17 重投 11.21 with editor 11.29～12.26 under review 12.26 返修 1.16 上传返修稿 1.18 第二次返修（要求上传路线图） 1.20上传 1.23 with editor 1.27 录用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sat Jan 28 09:22:33 CST 2023, time=2023-01-28, status=1, ipAttribution=新疆)]

2022-11-18 ms5000000350323787

请问一直没有审稿人接受审稿，是不是要被拒稿了？

29 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=801280, encodeId=fc388012800b, content=垃圾杂志，收了一堆造假的，在国外毫无地位可言，最近的论文工厂全是来自中国医院的造假文章，真几把丢人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Sun Jul 05 02:35:04 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2167319, encodeId=30a4216e31940, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：综述;心血管 经验分享：稿号：6403 9.13 submitted to journal 10.05 with editor 10.06 under review 10.13 revise 10.25 revision submitted 10.26 with editor 10.26 under review 11.03 required review completed 11.04 with editor 11.05 revise 11.06 revision submitted 11.07 with editor 11.08 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bd78523149, createdName=ms5000001229064995, createdTime=Wed Nov 08 02:10:09 CST 2023, time=2023-11-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2153849, encodeId=e4ba215384983, content=审稿速度:6.0 经验分享：with editor 20天了，发邮件催了也没用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17405591072, createdName=ms3000000829910165, createdTime=Mon Aug 21 13:15:55 CST 2023, time=2023-08-21, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2109558, encodeId=04b12109558ba, content=我是投爱思唯尔旗下其他期刊，然后建议改投这个的。我以为系统改投会快点。26号转投的，现在还是submitted to journal。。。效率这么慢的吗？要拒也早点拒，改投其他也好啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/0de91724d2aa47e0a583df4b2c253a26/e5494d41881e4175a8e5538a29e52895.jpg, createdBy=ded46480201, createdName=HuangWong, createdTime=Mon Jan 09 20:31:49 CST 2023, time=2023-01-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2101266, encodeId=545d210126690, content=请问一直没有审稿人接受审稿，是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=950c5610679, createdName=ms5000000350323787, createdTime=Fri Nov 18 09:37:50 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238808, encodeId=2df91238808f8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：最近撤稿了很多小RNA的文章，这个杂志又被好几家医院预警了，不知道今年的中科院预警名单会不会再上呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Mon Aug 15 15:19:38 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229452, encodeId=0585122945216, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：呼吸;中西医 经验分享：under review快一个月了，一直没有审稿人接收怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42a35638390, createdName=ms8000002141105059, createdTime=Wed Jun 29 13:59:44 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111801, encodeId=085c211180196, content=成分研究+药效+网药+机制研究 10.20 投稿（要求上传原始数据） 11.17 重投 11.21 with editor 11.29～12.26 under review 12.26 返修 1.16 上传返修稿 1.18 第二次返修（要求上传路线图） 1.20上传 1.23 with editor 1.27 录用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sat Jan 28 09:22:33 CST 2023, time=2023-01-28, status=1, ipAttribution=新疆)]

2022-08-15 小胖子罗军

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：中药单体
经验分享：最近撤稿了很多小RNA的文章，这个杂志又被好几家医院预警了，不知道今年的中科院预警名单会不会再上呢？

81 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=801280, encodeId=fc388012800b, content=垃圾杂志，收了一堆造假的，在国外毫无地位可言，最近的论文工厂全是来自中国医院的造假文章，真几把丢人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Sun Jul 05 02:35:04 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2167319, encodeId=30a4216e31940, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：综述;心血管 经验分享：稿号：6403 9.13 submitted to journal 10.05 with editor 10.06 under review 10.13 revise 10.25 revision submitted 10.26 with editor 10.26 under review 11.03 required review completed 11.04 with editor 11.05 revise 11.06 revision submitted 11.07 with editor 11.08 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bd78523149, createdName=ms5000001229064995, createdTime=Wed Nov 08 02:10:09 CST 2023, time=2023-11-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2153849, encodeId=e4ba215384983, content=审稿速度:6.0 经验分享：with editor 20天了，发邮件催了也没用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17405591072, createdName=ms3000000829910165, createdTime=Mon Aug 21 13:15:55 CST 2023, time=2023-08-21, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2109558, encodeId=04b12109558ba, content=我是投爱思唯尔旗下其他期刊，然后建议改投这个的。我以为系统改投会快点。26号转投的，现在还是submitted to journal。。。效率这么慢的吗？要拒也早点拒，改投其他也好啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/0de91724d2aa47e0a583df4b2c253a26/e5494d41881e4175a8e5538a29e52895.jpg, createdBy=ded46480201, createdName=HuangWong, createdTime=Mon Jan 09 20:31:49 CST 2023, time=2023-01-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2101266, encodeId=545d210126690, content=请问一直没有审稿人接受审稿，是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=950c5610679, createdName=ms5000000350323787, createdTime=Fri Nov 18 09:37:50 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238808, encodeId=2df91238808f8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：最近撤稿了很多小RNA的文章，这个杂志又被好几家医院预警了，不知道今年的中科院预警名单会不会再上呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Mon Aug 15 15:19:38 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229452, encodeId=0585122945216, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：呼吸;中西医 经验分享：under review快一个月了，一直没有审稿人接收怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42a35638390, createdName=ms8000002141105059, createdTime=Wed Jun 29 13:59:44 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111801, encodeId=085c211180196, content=成分研究+药效+网药+机制研究 10.20 投稿（要求上传原始数据） 11.17 重投 11.21 with editor 11.29～12.26 under review 12.26 返修 1.16 上传返修稿 1.18 第二次返修（要求上传路线图） 1.20上传 1.23 with editor 1.27 录用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sat Jan 28 09:22:33 CST 2023, time=2023-01-28, status=1, ipAttribution=新疆)]

2022-06-29 ms8000002141105059

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：呼吸;中西医
经验分享：under review快一个月了，一直没有审稿人接收怎么办

2 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=801280, encodeId=fc388012800b, content=垃圾杂志，收了一堆造假的，在国外毫无地位可言，最近的论文工厂全是来自中国医院的造假文章，真几把丢人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Sun Jul 05 02:35:04 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2167319, encodeId=30a4216e31940, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：综述;心血管 经验分享：稿号：6403 9.13 submitted to journal 10.05 with editor 10.06 under review 10.13 revise 10.25 revision submitted 10.26 with editor 10.26 under review 11.03 required review completed 11.04 with editor 11.05 revise 11.06 revision submitted 11.07 with editor 11.08 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bd78523149, createdName=ms5000001229064995, createdTime=Wed Nov 08 02:10:09 CST 2023, time=2023-11-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2153849, encodeId=e4ba215384983, content=审稿速度:6.0 经验分享：with editor 20天了，发邮件催了也没用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17405591072, createdName=ms3000000829910165, createdTime=Mon Aug 21 13:15:55 CST 2023, time=2023-08-21, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2109558, encodeId=04b12109558ba, content=我是投爱思唯尔旗下其他期刊，然后建议改投这个的。我以为系统改投会快点。26号转投的，现在还是submitted to journal。。。效率这么慢的吗？要拒也早点拒，改投其他也好啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/0de91724d2aa47e0a583df4b2c253a26/e5494d41881e4175a8e5538a29e52895.jpg, createdBy=ded46480201, createdName=HuangWong, createdTime=Mon Jan 09 20:31:49 CST 2023, time=2023-01-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2101266, encodeId=545d210126690, content=请问一直没有审稿人接受审稿，是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=950c5610679, createdName=ms5000000350323787, createdTime=Fri Nov 18 09:37:50 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238808, encodeId=2df91238808f8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：最近撤稿了很多小RNA的文章，这个杂志又被好几家医院预警了，不知道今年的中科院预警名单会不会再上呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Mon Aug 15 15:19:38 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229452, encodeId=0585122945216, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：呼吸;中西医 经验分享：under review快一个月了，一直没有审稿人接收怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42a35638390, createdName=ms8000002141105059, createdTime=Wed Jun 29 13:59:44 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111801, encodeId=085c211180196, content=成分研究+药效+网药+机制研究 10.20 投稿（要求上传原始数据） 11.17 重投 11.21 with editor 11.29～12.26 under review 12.26 返修 1.16 上传返修稿 1.18 第二次返修（要求上传路线图） 1.20上传 1.23 with editor 1.27 录用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sat Jan 28 09:22:33 CST 2023, time=2023-01-28, status=1, ipAttribution=新疆)]

2024-05-16 ms9000000991394845 来自江苏省

投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了

13 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=801280, encodeId=fc388012800b, content=垃圾杂志，收了一堆造假的，在国外毫无地位可言，最近的论文工厂全是来自中国医院的造假文章，真几把丢人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=206, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Sun Jul 05 02:35:04 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2167319, encodeId=30a4216e31940, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：综述;心血管 经验分享：稿号：6403 9.13 submitted to journal 10.05 with editor 10.06 under review 10.13 revise 10.25 revision submitted 10.26 with editor 10.26 under review 11.03 required review completed 11.04 with editor 11.05 revise 11.06 revision submitted 11.07 with editor 11.08 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bd78523149, createdName=ms5000001229064995, createdTime=Wed Nov 08 02:10:09 CST 2023, time=2023-11-08, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2153849, encodeId=e4ba215384983, content=审稿速度:6.0 经验分享：with editor 20天了，发邮件催了也没用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17405591072, createdName=ms3000000829910165, createdTime=Mon Aug 21 13:15:55 CST 2023, time=2023-08-21, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2109558, encodeId=04b12109558ba, content=我是投爱思唯尔旗下其他期刊，然后建议改投这个的。我以为系统改投会快点。26号转投的，现在还是submitted to journal。。。效率这么慢的吗？要拒也早点拒，改投其他也好啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/0de91724d2aa47e0a583df4b2c253a26/e5494d41881e4175a8e5538a29e52895.jpg, createdBy=ded46480201, createdName=HuangWong, createdTime=Mon Jan 09 20:31:49 CST 2023, time=2023-01-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2101266, encodeId=545d210126690, content=请问一直没有审稿人接受审稿，是不是要被拒稿了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=950c5610679, createdName=ms5000000350323787, createdTime=Fri Nov 18 09:37:50 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238808, encodeId=2df91238808f8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：中药单体 经验分享：最近撤稿了很多小RNA的文章，这个杂志又被好几家医院预警了，不知道今年的中科院预警名单会不会再上呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/22/ca57c1c0c773c75300bbd8ed1699ece1.jpg, createdBy=6c7e2032247, createdName=小胖子罗军, createdTime=Mon Aug 15 15:19:38 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229452, encodeId=0585122945216, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：呼吸;中西医 经验分享：under review快一个月了，一直没有审稿人接收怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42a35638390, createdName=ms8000002141105059, createdTime=Wed Jun 29 13:59:44 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2111801, encodeId=085c211180196, content=成分研究+药效+网药+机制研究 10.20 投稿（要求上传原始数据） 11.17 重投 11.21 with editor 11.29～12.26 under review 12.26 返修 1.16 上传返修稿 1.18 第二次返修（要求上传路线图） 1.20上传 1.23 with editor 1.27 录用, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Sat Jan 28 09:22:33 CST 2023, time=2023-01-28, status=1, ipAttribution=新疆)]

2023-01-28 ms4000001680289394 来自新疆

成分研究+药效+网药+机制研究 10.20 投稿（要求上传原始数据） 11.17 重投 11.21 with editor 11.29～12.26 under review 12.26 返修 1.16 上传返修稿 1.18 第二次返修（要求上传路线图） 1.20上传 1.23 with editor 1.27 录用

53 7

展开7条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务